KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Sales and Divestitures: 2019

  • Amneal Pharmaceuticals' Gains from Sales and Divestitures was N/A to $479,299 in Q4 2019 from the same period last year, while for Dec 2019 it was $479,299, marking a year-over-year change of. This contributed to the annual value of $479,299 for FY2019, which is N/A change from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $479,299 for Q4 2019.
  • In the past 5 years, Amneal Pharmaceuticals' Gains from Sales and Divestitures registered a high of $479,299 during Q4 2019, and its lowest value of $479,299 during Q4 2019.
  • In the last 1 years, Amneal Pharmaceuticals' Gains from Sales and Divestitures had a median value of $479,299 in 2019 and averaged $479,299.